A drug to treat multiple sclerosis is one step closer to returning to market despite concerns it could trigger a rare brain disease. Helen Palmer reports the debate over the drug may harbinger a shift in FDA regulatory policy.

The Bank of Japan today ended a five-year policy that kept interest rates near zero. It's the first step toward an eventual rise in rates, something that's already happening in the U.S. and Europe. But Jocelyn Ford reports that the news isn't all bad.

AT&T should get an indication today of how its bid to acquire Bell South will be received by regulators. FCC nominee Robert McDowell will be asked about his opinion of the proposed merger at a Senate Commerce Committee hearing. Scott Tong reports.